DrugPatentWatch Database Preview
Drugs in Development Information for MGB-BP-3
» See Plans and Pricing
What is the drug development status for MGB-BP-3?
MGB-BP-3 is an investigational drug.
There have been 4 clinical trials for MGB-BP-3.
The most recent clinical trial was a Phase 1 trial, which was initiated on January 1st 2019.
The most common disease conditions in clinical trials are Vomiting, Postoperative Nausea and Vomiting, and Nausea. The leading clinical trial sponsors are MGB Biopharma Limited, Analytical Services International Limited, and Viapath.
There is one US patent protecting this investigational drug and thirteen international patents.
Summary for MGB-BP-3
| US Patents | 1 |
| International Patents | 13 |
| US Patent Applications | 1 |
| WIPO Patent Applications | 0 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 1 (2019-01-01) |
| Vendors | 7 |
Recent Clinical Trials for MGB-BP-3
| Title | Sponsor | Phase |
|---|---|---|
| Study to Assess Safety, Tolerability and Efficacy of Incremental Doses of MGB-BP-3 in Patients With CDAD | Syneos Health | Phase 2 |
| Study to Assess Safety, Tolerability and Efficacy of Incremental Doses of MGB-BP-3 in Patients With CDAD | MGB Biopharma Limited | Phase 2 |
| Effect of PNPLA3, TM6SF2 and MBOAT7 Genetic Variants on Non-alcoholic Fatty Liver Disease Therapeutic Outcome. | Federico II University | N/A |
Clinical Trial Summary for MGB-BP-3
Top disease conditions for MGB-BP-3
Top clinical trial sponsors for MGB-BP-3
US Patents for MGB-BP-3
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| MGB-BP-3 | Start Trial | Minor groove binders | University of Strathclyde (Glasgow, GB) | Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for MGB-BP-3
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| MGB-BP-3 | Canada | CA2664847 | 2026-09-30 | Start Trial |
| MGB-BP-3 | China | CN101589024 | 2026-09-30 | Start Trial |
| MGB-BP-3 | Denmark | DK2066627 | 2026-09-30 | Start Trial |
| MGB-BP-3 | European Patent Office | EP2066627 | 2026-09-30 | Start Trial |
| MGB-BP-3 | Spain | ES2443720 | 2026-09-30 | Start Trial |
| MGB-BP-3 | United Kingdom | GB0619325 | 2026-09-30 | Start Trial |
| MGB-BP-3 | United Kingdom | GB0906908 | 2026-09-30 | Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
